IBI3001 在患有不可切除、局部晚期或转移性实体瘤的参与者中的应用
IBI3001 在患有不可切除、局部晚期或转移性实体瘤受试者中的 1/2 期研究
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
学习地点
-
-
Anhui
-
Hefei、Anhui、中国、230022
- 招聘中
- The First Affiliated Hospital of Anhui Medical University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- 招聘中
- Cancer Hospital, Chinese Academy of Medical Sciences
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Beijing、Beijing Municipality、中国、100853
- 招聘中
- Chinese People's Liberation Army General Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 招聘中
- Fujian Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Fuzhou、Fujian、中国、350005
- 招聘中
- First Affiliated Hospital, Fujian Medical University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- 招聘中
- The Affiliated Tumor Hospital of Guangxi Medical University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- 招聘中
- Harbin Medical University Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang、Henan、中国、455100
- 招聘中
- Anyang Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Luoyang、Henan、中国、471003
- 招聘中
- The First Affiliated Hospital of Henan University of Science and Technology
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Zhengzhou、Henan、中国、450008
- 招聘中
- Henan Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Zhengzhou、Henan、中国、450052
- 招聘中
- The First Affiliated Hospital of Zhengzhou University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 招聘中
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha、Hunan、中国、410008
- 招聘中
- Xiangya Hospital, Central South University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- 招聘中
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Nanjing、Jiangsu、中国、210029
- 招聘中
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330029
- 招聘中
- Jiangxi Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200120
- 招聘中
- Shanghai East Hospital, Tongji University School of Medicine
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 招聘中
- West China Hospital, Sichuan University
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Chengdu、Sichuan、中国、610041
- 招聘中
- Sichuan Cancer Hospital & Institute
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310022
- 招聘中
- Zhejiang Cancer Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
Hangzhou、Zhejiang、中国、310003
- 招聘中
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
-
-
New South Wales
-
Wollongong、New South Wales、澳大利亚、2500
- 招聘中
- Wollongong Hospital
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- 招聘中
- Cancer Research SA
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles、California、美国、90025
- 招聘中
- START Center for Cancer Research
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- 招聘中
- START Center for Cancer Research
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas、Texas、美国、75039
- 招聘中
- NEXT Oncology
-
接触:
- Fortvita Biologics CT.gov Call Center
- 电话号码:650-370-0985
- 邮箱:ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 主动,不招人
- Virginia Cancer Specialists
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:开放标签:IBI3001单一疗法
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of subjects with adverse events
大体时间:24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
大体时间:24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
大体时间:24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
大体时间:24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
大体时间:24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
大体时间:24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
大体时间:24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
大体时间:24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
大体时间:24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
大体时间:24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
大体时间:24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
大体时间:24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
大体时间:24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
大体时间:24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
大体时间:24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
大体时间:24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
大体时间:24 months
|
Overall survival. |
24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- CIBI3001A101
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.